Chardan Capital Begins Coverage on Stoke Therapeutics (NASDAQ:STOK)

Investment analysts at Chardan Capital started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued on Friday, Marketbeat.com reports. The firm set a “buy” rating and a $24.00 price target on the stock. Chardan Capital’s price target suggests a potential upside of 105.48% from the stock’s previous close.

A number of other brokerages have also commented on STOK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partners started coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Up 3.4 %

Shares of Stoke Therapeutics stock opened at $11.68 on Friday. The stock’s fifty day moving average is $12.48 and its two-hundred day moving average is $13.54. Stoke Therapeutics has a 52 week low of $4.09 and a 52 week high of $17.58. The company has a market capitalization of $618.65 million, a PE ratio of -5.56 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. As a group, research analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the sale, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This represents a 16.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 13,666 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now owns 21,476 shares in the company, valued at approximately $292,288.36. This trade represents a 38.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock worth $809,421 over the last quarter. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Exome Asset Management LLC acquired a new position in shares of Stoke Therapeutics during the third quarter valued at about $2,170,000. Barclays PLC grew its position in Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares during the last quarter. Geode Capital Management LLC increased its stake in Stoke Therapeutics by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after purchasing an additional 76,661 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Stoke Therapeutics by 338.2% in the third quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock worth $4,061,000 after buying an additional 255,028 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after buying an additional 137,145 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.